Lack of effect of a new spasmolytic agent, rociverine, on intraocular pressure, pupil size and iridocorneal angle in patients with angle-closure glaucoma
Twenty patients with angle-closure glaucoma (38 glaucomatous eyes - 17 surgically operated, 21 non-operated) were treated with rociverine (60 mg orally per day for 7 days), a new direct myolitic and mildly anticholinergic antispasmodic drug. Intraocular pressure, pupil size, iridocorneal angle, bloo...
| Veröffentlicht in: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 3(1983), 7 vom: 03., Seite 445-50 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | |
| Format: | Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
1983
|
| Zugriff auf das übergeordnete Werk: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC) |
| Schlagworte: | Journal Article Bridged Bicyclo Compounds Bridged-Ring Compounds Cyclohexanecarboxylic Acids Parasympatholytics rociverine VI08KS44V0 |
| Zusammenfassung: | Twenty patients with angle-closure glaucoma (38 glaucomatous eyes - 17 surgically operated, 21 non-operated) were treated with rociverine (60 mg orally per day for 7 days), a new direct myolitic and mildly anticholinergic antispasmodic drug. Intraocular pressure, pupil size, iridocorneal angle, blood pressure and heart rate were checked before and during treatment. No clinically significant variations were observed in the parameters tested. It is suggested, therefore, that rociverine may be administered, if necessary, even to patients with angle-closure glaucoma |
|---|---|
| Beschreibung: | Date Completed 30.03.1984 Date Revised 23.11.2016 published: Print Citation Status MEDLINE |